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1. Introduction 
Echinococcosis is a zoonotic infection caused by adult or larval (metacestode) stages of 
cestodes belonging to the genus Echinococcus and the family Taeniidae. Life cycles imply two 
mammal hosts. Definitive hosts are carnivores containing adult forms in the gut. The 
infection is acquired by the intermediate hosts and humans after the ingestion of eggs from 
the feces of carnivorous definitive hosts, which harbour the adult egg-producing stage in the 
intestine. Eggs ingested by infected human develop into the infective metacestode stage 
causing various forms of Echinococcosis. The disease in humans and intermediate hosts is 
called Hydatidosis and is characterized according to the morphologic features of the larval 
stages: cystic echinococcosis (CE) caused by Echinococcus granulosus and related organisms, 
alveolar echinococcosis (AE) caused by Echinococcus multilocularis, and polycystic 
echinococcosis (PE) caused by Echinococcus vogeli or Echinococcus oligarthrus.  
This disease is becoming an important public health problem in many parts of the world 
where dogs are used for cattle breeding. Control measures are unable to be implemented 
everywhere, and where control programs were initiated the success of them have been 
incomplete generating a re-emergence of the disease. This has also lead to the interruption 
of control measures excluding Echinococcosis from the list of notifiable diseases. As a 
consequence of this the incidence and prevalence of CE in Mediterranean countries in 
humans and animals are not known (Dakkak, 2010). Also, there are a number of factors that 
contribute to the increase of prevalence and to the spreading of CE in the Mediterranean 
Region. Cyprus is the only country where an eradication programme has been successfully 
implemented. However, CE has obtained important developments in the last decade, in the 
epidemiology, in the diagnosis of canine infection, in strain characterisation and in immune 
strategies against CE in animals. This scientific progress, together with effective health 
education programmes, will likely improve control programmes and reduce the time 
required to achieve significant decreases in prevalence or eradication. Thus, European 
authorities recognized, through the directive 2003/99/CE, Echinococcosis as a disease to be 
reported to the European Food Safety Authority (EFSA).  
The “WHO/OIE Manual on Echinococcosis in Humans and Animals: a Public Health 
Problem of Global Concern”, published in 2001, has been used as a fundamental issue for 
the redaction of this chapter.  
2. Echinococcosis 
The first part of this chapter is dedicated to explain the etiology to know the taxonomy and 
the life transmission cycles which perpetuate the agent in nature. The biology of the 
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causative agents of various forms of Echinococcosis is faced because it can help to 
understand the maintaining of these parasites in different geographic areas. Following to 
this part the epidemiology and clinical presentation forms are assessed. Finally, diagnosis, 
treatment and prevention are developed and emphasis is given to the identification of 
species and strains within the genus as an essential prerequisite to the establishment of local 
control programmes. 
2.1 Etiology and life cycles  
Echinococcus presents certain unique characteristics that set it apart from the other major 
genus in the family, Taenia. The adult form is only few millimetres long, has no gut and all 
metabolic interchange takes place across the syncytial outer covering, the tegument. Scolex 
is the anterior part of the Echinococcus becoming an attachment organ with four muscular 
suckers and two rows of hooks. The body is the strobila and is segmented in a different 
number of reproductive units called proglottids. The adult worm is hermaphrodite with 
reproductive ducts opening at a common, lateral, genital pore, the position of which may 
vary depending on species and strain. The uterus dilates after fertilisation, eventually 
occupying most of the terminal segment when the eggs are fully developed. The eggs are 
ovoid, consisting of a hexacanth embryo surrounded by several envelopes and are 
morphologically indistinguishable to those of other tapeworms of the genus Taenia. The 
metacestode is the second larval stage and consists of a bladder with an outer acellular 
laminated layer and an inner nucleated germinal layer. Protoscoleces arise from the inner 
wall of the brood capsules (figure 1). The structure and development of the metacestode 
differs between the four species of Echinococcus.  
 
 
Fig. 1. Representation of the metacestode of Echinococcus granulosus (WHO/OIE publication: 
Manual on echinococcosis in humans and animals) 
The life cycle of Echinococcus spp. requires two mammalian hosts for its completion. Gravid 
proglottids containing eggs or free eggs are passed in the faeces of the definitive host, a 
carnivore. These eggs are ingested by an intermediate host, in which the metacestode stage 
and protoscoleces develop. The cycle is completed if such an intermediate host is eaten by a 
suitable carnivore. Eggs are highly resistant to the environmental factors being infective for 
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months at lower ranges of temperatures (from +4ºC to +15ºC). However, they are very 
sensitive to desiccation and to high temperatures as 60-80ºC.  
Intermediate hosts are represented by a wide range of mammals which acquire the infection 
by the ingestion of eggs. The oncosphere is released from the keratinised embryophore in 
the stomach and small intestine. Bile activates the oncosphere which penetrates the wall due 
to the hook movements and secretions and arrives to the liver where some of them are 
retained (figure 2). All mammals (including man) in which metacestodes of Echinococcus 
species develop after infection with eggs may be referred to as ‘intermediate hosts’. 
However, man is an aberrant host because metacestode stages do not become fertile in this 
host or because does not interact in the transmission cycle. Once the oncosphere has reached 
its final location, it develops into the metacestode stage. Time of development is variable 
and it may take several months before protoscoleces are produced (fertile metacestode). 
There may be several thousand protoscoleces within a single cyst of E. granulosus or an 
aggregation of vesicles of E. multilocularis. Each single protoscolex is capable of developing 
into a sexually mature adult worm. Not all metacestodes produce protoscoleces (sterile 
metacestode). 
 
 
Fig. 2. Life-cycle of Echinococcus (WHO/OIE publication: Manual on echinococcosis in 
humans and animals)  
Strain identification is possible for all four species of Echinococcus using morphological and 
biological features and/or molecular techniques, such as sequence comparison of a 366 bp-
fragment of the mitochondrial cytochrome oxidase subunit 1 DNA (CO1) and a 471 bp-
region in the mitochondrial NADH dehydrogenase gene 1 (ND1), by analysis of a ribosomal 
(r) DNA fragment (1ST2) or by the random amplified polymorphic DNA-PCR (RAPD-PCR). 
Recent genetic studies have principally confirmed the concept of strain diversity within the 
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species E. granulosus, previously based on morphological and biological features. Several 
molecular techniques are now available which would quite easily allow the identification of 
certain E. granulosus strains using genetic markers. To prepare the identification of the strain 
using molecular techniques protoscoleces are collected from E. granulosus cysts being 
washed several times in physiological saline solution and preserved in 70% ethanol. The 
material needs to be examined by an experienced laboratory. The rDNA ITS1 (internal 
transcribed spacer) region has been shown to be a potentially very useful genetic marker for 
distinguishing strains and species of Echinococcus and small quantities of Echinococcus 
material can be characterised using a PCR-RFLP ‘fingerprinting’ technique (Bowles & 
McManus, 1993).  Other method is the single strand conformation polymorphism (SSCP) 
which is technically simple and has high resolution capacity under optimised conditions. 
The utility of SSCP has been demonstrated for the categorisation of different Echinococcus 
genotypes (Gasser et al., 1998). The different strains of Echinococcus have an epidemiological 
significance for the prognosis in infected patients. Epidemiological studies have evidenced 
that the sylvatic strain of E. granulosus in northern North America is causing a benign 
infection with low pathogenicity, and affecting the lungs. Also, these epidemiological 
observations have been demonstrated in the People’s Republic of China. In contrast, in parts 
of Kenya and Libya, it has been suggested that there are local virulent strains of E. 
granulosus (Thompson, 1995). Isoenzyme and molecular studies have confirmed that sheep 
strain is infective to humans (Bowles & McManus, 1993). Developmental differences 
between species and strains of Echinococcus are likely to be a limiting factor in control 
programmes which employ regular adult cestocidal treatment of definitive hosts for 
breaking the cycle of transmission (Thompson, 1995). 
2.2 Clinical forms of Echinococcosis 
The metacestodes of all four recognised Echinococcus species can infect humans and cause 
various forms of echinococcosis (Table 1). Among these forms cystic and alveolar 
echinococcosis are of special medical importance. 
 
Forms of 
Echinococcosis 
Causative agent Disease synonyms 
Cystic 
Echinococcosis 
Echinococcus 
granulosus 
Hydatid disease, Hydatidosis, E. 
granulosus echinococcosis 
Alveolaar 
Echinococcosis 
Echinococcus 
multilocularis 
Alveolar hydatid disease, E. multilocularis 
echinococcosis 
Polycystic 
Echinoccosis 
Echinococcus vogeli E.vogeli echinococcosis 
Polycystic 
Echinococcosis 
Echinococcus 
oligarthrus 
E. oligarthrus echinococcosis 
Table 1. Forms of Echinococcosis 
Primary echinococcosis is established when metacestodes develop in various sites of the 
human body from oncospheres liberated from ingested eggs of Echinococcus spp. In CE liver 
and lung are the most frequently affected organs.  
Secondary echinococcosis occurs when metacestode material spreads from primary site to 
adjacent or distant organs and proliferates. Regarding CE this form occurs after release of 
viable parasite material during invasive treatment procedures.  
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2.2.1 Cystic echinococcosis (CE) 
The causative agent of CE is the metacestode of Echinococcus granulosus, becoming a cystic 
structure filled with a clear fluid. Most of the cysts grow slowly in size and become 
surrounded by host tissue (pericyst) encompassing the endocyst of metacestode origin. The 
endocyst consists of the outer laminated layer and the inner cellular germinal layer, which 
may form brood capsules and protoscoleces. The minimum time required for the 
development of protoscoleces in cysts in humans is not exactly known, but it is expected to 
be 10 months or longer after infection (Pawlowski, 1997). Fertile (with protoscoleces) and 
sterile (without protoscoleces) cysts may coexist in the same patient. Frequently, smaller 
daughter cysts are formed within a larger mother cyst. If these smaller cysts are growing in 
close proximity to each other forming clusters the appearance of “polycystic” needs to be 
distinguished from AE or PE. 
The initial phase of primary infection is always asymptomatic remaining as this for many 
years or permanently. However, the infection may become symptomatic when cysts press 
adjacent tissues or induce other pathological events. When symptoms appear suddenly a 
spontaneous or traumatic cyst rupture has to be suspected. Spontaneous cure is possible but 
improbable, and is due to the collapse and resolution of cysts or due to the cyst rupture into 
the bile duct or the bronchial tree. The fatality rate is highly dependent on the severity of the 
infection and on facilities for treatment.    
The age of the symptomatic infected patients can vary from below 1 year of age to over 75 
years old.  In a study from Madrid (Spain), over 1,473 patients admitted to a children’s 
hospital, 2%were <1 year old, 21% between 1 and 4 years and 77% between 5 and 14 years 
(Utrilla et al., 1991). Many patients (about 40% up to 80%) with CE have a single organ 
involved and harbour a solitary cyst. 
2.2.1.1 Clinical presentation of CE 
Clinical symptoms of CE are variable and depend on the organ involved, the size of the 
cysts, the interaction between the expanding cysts and the adjacent organ structures, and the 
complications related to the cyst rupture and bacterial infection. CE involving the liver can 
remain asymptomatic for more than ten years (Frider et al., 1999).  Liver and lungs are the 
two more frequent organ sites involved. Complications affecting the biliary tract are the 
most common and include the cystic rupture into bile ducts. Other complications are 
bacterial infection of the cyst, intraperitoneal rupture, and lung involvement.  
2.2.1.2 Diagnosis of CE 
Diagnosis of CE is done through different steps as follows: 
a. Clinical suspect or screening 
b. Confirmation by imaging and identification of suspicious cyst structures 
c. Confirmation by detection of specific antibodies with immunodiagnostic tests 
d. If doubt diagnostic puncture may be considered 
e. Material obtained by biopsy puncture or surgery is examined. 
Ultrasonography (US) is used for the diagnosis of the cystic structure and portable units are 
suitable to take into account in field situations. Immunodiagnostic tests for detecting specific 
antibodies are commonly used for the aetiological confirmation of the findings of imaging 
examinations.  
Protoscoleces or hooks of E. granulosus are found in aspirated fluid samples. This technique 
is not performed frequently because the material can only be available after a surgical 
intervention, therapeutic puncture (PAIR) or diagnostic puncture. Direct diagnosis can also 
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be made by macroscopic identification of the E. granulosus obtained by surgery or biopsy. 
Other methods include the identification of specific E. granulosus antigen (antigen 5) in the 
fluid from sterile cysts or DNA markers in the cysts fluid or parasite tissue (e.g. by PCR). 
Imaging techniques for diagnosis: 
 Standard radiology: chest radiography detects uncomplicated cyst structures displaying 
a homogeneous shadow that indicates a fluid-filled space. Calcification in lung imaging 
is rare and cysts may be located anywhere as solitary or multiple. For differential 
diagnosis, cysts filled with clear fluid, with an air shadow or with water-lily sign are 
pathognomonic. If a rounded parenchymatous opacity is seen, it is necessary to 
consider tuberculoma, a tumour or pulmonary sequestration. A fluid and air shadow 
will lead to consideration of a bacterial, fungal or amoebic abscess.  
 Ultrasonography (US): an expert committee of the WHO Working Group on 
echinococcosis presented an internationally agreed classification of US images in 
hepatic CE in 2001 (WHO, 2001), according to the use of PAIR (Puncture, Aspiration, 
Injection, Re-aspiration). This technique was proposed in 1986 by the Tunisian team 
that first used it in a prospective study. PAIR is a minimally invasive therapeutic option 
for percutaneous drainage of echinococcal cysts located in the abdomen, 
complementing or replacing surgery in most of the settings. PAIR also helps the use of 
benzimidazoles (albendazole and mebendazole) for the treatment of CE. The drainage 
is performed with a fine needle or a catheter, followed by the killing of the protoscolices 
remaining in the cyst cavity by a protoscolicide agent. If numerous and large daughter 
cysts are present, an alternative percutaneous technique “Percutaneous Puncture with 
Drainage and Curettage” (PPDC) may be used.  
 
 
Fig. 3. Image from a computed tomography study of the abdomen of a patient (Soriano 
Arandes et al., 2010). 
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 Computed tomography (CT) can detect small cysts, and it also facilitates differential 
diagnosis of lesions caused by Echinococcus metacestodes from non-parasitic lesions 
(figure 3) (Soriano Arandes et al., 2010). CT is only indicated when US diagnosis is 
uncertain, mainly in cysts CE4 or CE5. However, CT is the principal method for 
diagnosis of cerebral cysts showing a spherical cyst with a thin wall, not enhanced after 
injection of contrast medium, without perilesional oedema the adjacent structures. 
2.2.1.3 WHO classification of CE 
The WHO classification of CE cysts (WHO, 2001) is done according to the US images: 
 
 
CL           CE1      CE2               CE3         CE4               CE5 
Cystic lesion (CL): Unilocular, cystic lesion (s) (CL) with uniform anechoic content, not 
clearly delimited by a hyperechoic rim (= cyst wall not visible). 
 Normally round but may be oval. 
 Size: variable but usually small. CLs (< 5.0 cm), CLm (5 – 10 cm), CLl (> 10cm). 
 Status: If CE - active.If these cystic lesions are caused by CE at an early stage of 
development then usually these cysts are not fertile. 
 Ultrasound does not detect any pathognomonic signs. 
 Differential diagnosis of these cystic lesions requires further diagnostic techniques. 
CE1: Unilocular, simple cyst with uniform anechoic content. Cyst may exhibit fine echoes due 
to shifting of brood capsules which is often called hydatid sand (“snow flake sign”) (figure 4). 
 
 
Fig. 4. Hydatid sand containing a protoscolex of Echinococcus granulosus seen by light 
microcopy (Soriano Arandes et al., 2010). 
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 Cyst wall is visible. 
 Normally round or oval. 
 Size variable: CE1s (< 5.0 cm), CE1m (5 – 10 cm), CE1l (> 10cm) 
 Status: active. 
 Usually fertile. 
 Pathognomonic signs include visible cyst wall and snow flake sign. 
CE2: Multivesicular, multiseptated cysts; cysts septations produce “wheel-like” structures, 
and presence of daughter cysts is indicated by “rosette-like” or “honeycomb-like” 
structures. Daughter cysts may partly or completely fill the unilocular mother cyst. 
 Cyst wall normally visible. 
 Normally round or oval. 
 Size variable: CE2s (< 5.0 cm), CE2m (5 – 10 cm), CE2l (> 10cm). 
 Status: active. 
 Usually fertile. 
 Ultrasound features are pathognomonic. 
CE3: Unilocular cyst which may contain daughter cysts. Anechoic content with detachment 
of laminated membrane from the cyst wall is visible as floating membrane or as “water-lily 
sign” which is indicative of wavy membranes floating on top of remaining cyst fluid. 
 Cyst form may be less rounded because of decrease of intra-cystic fluid pressure. 
 Size variable: CE3s (< 5.0 cm), CE3m (5 – 10 cm), CE3l (> 10cm). 
 Status: transitional. 
 Transitional stage. Cyst which may degenerate further or may give rise to daughter 
cysts. 
 Ultrasound features are pathognomonic. 
CE4: Heterogenous hypoechoic or hyperechoic degenerative contents. No daughter cysts. 
 May show a “ball of wool” sign which is indicative of degenerating membranes. 
 Size variable: CE4s (< 5.0 cm), CE4m (5 – 10 cm), CE4l (> 10cm). 
 Status: inactive. 
 Most cysts of this type are not fertile. 
 US features are not pathognomonic and further diagnostic tests are required to 
ascertain a diagnosis. 
CE5: Cysts characterized by thick calcified wall that is arch shaped, producing a cone 
shaped shadow.  
 Degree of calcification varies from partial to complete. 
 Size variable: CE5s (< 5.0 cm), CE5m (5 – 10 cm), CE5l (> 10cm). 
 Status: inactive. 
 Cyst not fertile in most cases. 
 Diagnosis is uncertain. Features are not pathognomonic but highly suggestive for E. 
granulosus. 
2.2.1.4 Laboratory findings of CE 
Routine laboratory tests show non-specific results. Patients with rupture of a cyst into the 
biliary tree can show transient elevations of GGT or alkaline phosphatase concentrations, 
often associated with hyperamylasaemia and eosinophilia (>500/µl). When cyst is ruptured 
eosinophilia achieves higher concentrations.  
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2.2.1.5 Immunodiagnosis of CE 
Immunodiagnosis procedures for serum antibody detection are used for the aetiological 
confirmation of imaging structures suggestive for CE. Certain proportion of patients with 
echinococcosis is unable to be diagnosed with highly sensitive diagnostic tests such as IgG-
ELISA and false-negative results are obtained. Cysts in the brain or eye and calcified cysts 
often induce low or no antibody titres. Antibody response may also be low in certain human 
population groups and in young children. False positive results may also occur, especially in 
patients with other helminthic diseases. Approaches to the diagnosis of CE using immune 
methods are specified in table 2.  
 
Fisrt step: Primary antibody test 
Test for serum antibody detection: IgG-ELISA or IgE-ELISA with E. Granulosus antigen 
A combination of two or more primary tests may increase sensitivity 
Subsequent steps 
Seronegative samples 
+ 
No suggestive images 
for CE 
Seronegative samples 
+ 
Suggestive images for 
CE 
Seropositive samples 
+ 
With or without suggestive 
images for CE 
No further serological 
follow-up or further 
steps for differential 
diagnosis 
Asymptomatic cases 
Extended and/or 
advanced imaging 
and repeated serological 
examinations, 
including differential 
diagnosis for 
AE* 
‘Wait and observe’ 
approach with 
repeated serological 
examinations 
Asymptomatic and 
symptomatic cases 
Secondary antibody test: 
Arc 5 test 
IgG4-ELISA 
Immunoblot for antibodies 
reactive with subunits of 
E. granulosus antigens 
Serological differential diagnosis 
for AE (ELISA-Em2plus, 
immunoblot) 
 
Symptomatic cases 
Consideration of cyst 
puncture 
Consideration of surgical 
intervention 
and/or chemotherapy 
without further 
serological examinations 
Table 2. Approaches for immunodiagnosis of CE  
IgG-ELISA is the preferable test used as a primary test for detecting anti-Echinococcus serum 
antibodies. Most of the routine laboratory test systems or commercialized test kits are based 
on crude or semi-purified preparations of E. granulosus antigens. The use of the two major 
hydatid cyst fluid antigens, antigen 5 (thermolabile) and antigen B (thermostable), is 
predominantly restricted to scientific applications, and these antigens are not generally 
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available. Secondary tests for antibody detection are used to increase specificity and these 
are: arc 5, identification of IgG subclasses, and immunoblotting which demonstrates the 
reactivity of serum antibodies with subunits of E. granulosus antigens (Craig, 1997; Di Felice, 
1986; Ioppolo, 1996; Leggatt & McManus, 1994; Leggatt, 1992; Ligthowlers & Gottstein, 1995; 
Profumo, 1994; Sheperd & McManus, 1987; Siracusano & Vuitton, 1997; Wen & Craig, 1994). 
Generally, these tests are less sensitive, but more specific than primary test systems. Putative 
hydatid cyst fluid samples obtained by puncture or after surgical intervention can be tested 
for the presence or absence of Echinococcus antigen through binding of enzyme-labelled anti-
Echinococcus (hydatid cyst fluid) antibodies in an ELISA with a monoclonal antibody against 
antigen 5 (Ag5) that may be useful in confirmation of the Echinococcus nature of the fluid 
(Paul & Stefaniak, 1997). 
2.2.1.6 Treatment of CE 
Surgery is still the treatment that has the potential to remove E. granulosus cysts and lead to 
complete cure (WHO, 1996). Up to 90% of the patients can be treated surgically if a cyst does 
not have a risky localisation or if the disease is not too far advanced. However, surgery may 
be impractical in patients with multiple cysts localised in several organs and if surgical 
facilities are inadequate. Chemotherapy and PAIR offer an attractive option for treatment, 
especially in inoperable patients and for cases with a high surgical risk.  
2.2.1.6.1 Surgery 
Surgery is indicated for large liver cysts with multiple daughter cysts; single liver cysts, 
situated superficially that may rupture spontaneously or as a result of trauma; cysts that are 
infected; cysts communicating with biliary tree and/or exerting pressure on adjacent vital 
organs; cysts in the lung, brain and kidney, bones and other organs. 
Surgery of CE is contraindicated as defined for surgical procedures in general, i.e. patients 
refusing surgery, patients at the extremes of age, pregnant women, and patients with 
concomitant severe diseases (i.e. cardiac, renal or hepatic diseases, diabetes and hypertension). 
Also, surgery is contraindicated in patients with multiple cysts or cysts difficult to access, dead 
cysts either partly or totally calcified, and in patients with very small cysts. 
The protoscolicides appareantly effective are: 70-95% ethanol, 15-20% hypertonic saline 
solution, and 0.5% cetrimide solution. These substances should be left in the cyst cavity for 
at least 15 minutes to obtain an optimal efficacy.  
The risks of surgical intervention include secondary echinococcosis owing to spillage of 
viable parasite material during the intervention. Recurrence can be due to incomplete cyst 
removal or to previously undetected cysts. Anaphylactic reactions represent a further risk 
on rare occasions. Postoperative fatality is about 2% or less, but may be higher in the second 
or further operations or if medical facilities are inadequate.  
2.2.1.6.2 Puncture, aspiration, injection, re-aspiration (PAIR) 
This technique includes the following steps (WHO, 2001): 
 percutaneus puncture of cysts under ultrasonic guidance 
 aspiration of a substantial amount of cyst fluid 
 injection of protoscolicidal substance (preferably 95% ethanol) 
 re-aspiration of the fluid cyst content after 15 min to 20 min. 
PAIR should be accompanied by a chemotherapeutic coverage to minimise risks of 
secondary echinococcosis and should be reserved for use by skilled and well experienced 
physicians with a surgical and intensive care back-up team well prepared to deal 
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immediately with complications. Aspirates of liver cysts must be analysed immediately for 
traces of bilirubin and protoscoleces or hooks. PAIR should only be performed under 
chemotherapeutic coverage, except in early pregnant patients (Filice & Brunetti, 1997). 
The PAIR sequence is (WHO, 2001):  
 
 
There are some critical points to take into account when proceeding with the PAIR protocol: 
 Prophylaxis pre- and post-procedure: albendazole is administered 24 to 4 hours before 
intervention and 15 days to 30 days after intervention according to the cystic size. No 
treatment for pregnant women.  
 Communication with biliary tree: the minimum requirements are to search for bile in 
the fluid with fast test. 
 Scolicidal agent to be used: hypertonic saline (at least 15% final concentration in cyst) or 
95% alcohol. 
 Quantity of scolicide injected: at least 1/3 of the aspirated quantity. 
 Evaluation of viability: microscopic examination. 
 Needle vs. catheter: needle for cysts <5 cm. or in multiloculated cysts. Catheter for cysts 
>5 cm. (PAIRD) 
 Follow-up: every week for the 1st month, then every month for the 1st year, the every 
year for 10 years. 
Indications for PAIR: we use this technique for patients with: 
 Non-echoic lesion ≥ 5 cm in diameter (CE1m and l) 
 Cysts with daughter cysts (CE2), and/or with detachment of membranes (CE3) 
 Multiple cysts if accessible to puncture 
 Infected cysts 
 Also for pregnant women, children >3 years old, patients who fail to respond to 
chemotherapy alone, patients in whom surgery is contraindicated, patient who refuse 
surgery, and patients who relapse after surgery. 
Contraindications for PAIR: 
 Non-cooperative patients and inaccessible or risky location of the cyst in the liver 
 Cyst in spine, brain and/or heart 
 Inactive or calcified lesion 
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 Cysts communicating with the biliary tree 
 Cysts open into the abdominal cavity, bronchi and urinary tract. 
2.2.1.6.3 Chemotherapy 
The documentation of the experience about chemotherapy with benzimidazoles in CE is 
now extensive. Third part of the patients treated with benzimidazoles is achieving the cure 
with a complete and definitive disappearing of the cysts, and higher proportion (30-50%) 
has obtained a considerable reduction of the cyst size and also relieve of their symptoms. 
However, 20-40% of the cases don’t respond as expected. Smaller and isolated cysts (less 
than 7mm.), surrounded by a minimal adventitial membrane respond better than 
complicated with multiple separations or with son cysts, or surrounded by a thick or 
calcified  adventitial membrane which are refractory to the treatment. There are two main 
drugs for chemotherapy: albendazole (10-15 mg/kg/day twice per day; 3- to more than 6 
monthly courses with free intervals of 14 days) for treating patients with single or multiple 
cysts (Gemmell & Roberts, 1995), and mebendazole (40-50 mg/kg/day; everyday in three 
doses per day during 3-6 months). Albendazole continuous courses have shown equal or 
improved efficacy for 3 to 6 months or longer without an increase of adverse effects (Franchi 
et al., 1999). When comparing both drugs, albendazole and mebendazole, some researchers 
concluded that albendazole was better regarding complete cure rates and relieve of the 
symptoms (Franchi et al., 1999). Albendazole has a better pharmacokinetic profile than 
mebendazole facilitating higher intestinal absorption and penetration into the cysts. There 
are described some adverse reactions (neutropenia, hepatic toxicity, alopecia, and others) in 
a few number of patients which are reversible when treatment is interrupted. Doses, 
duration, and follow-up of treatment must be taken individually for each patient. However, 
it seems that minimum duration has to be for three months. It is difficult to predict the long-
term prognosis for every patient; therefore it’s necessary to do a long-term follow-up, with 
US or other imaging methods to be able to evaluate the result of the treatment. 
Chemotherapy is also useful as a surgical complement and albendazole has been used as a 
pre-surgical treatment to facilitate the surgical manipulation of the cysts inactivating the 
protoscoleces previously, modifying the integrity of the cyst membranes and reducing the 
consistency of the cysts. Treatment with benzimidazoles is recommended to prevent the 
relapse of the disease, which is the secondary echinococcosis when the content of the cysts is 
spread after its spontaneous or accidental rupture. When it occur the best option is to treat 
with three cycles of albendazole or the continuous administration of mebendazole during 1-
3 months. 
Praziquantel at doses of 40 mg/kg is a potent protoscolicide and could be used as a 
preventive drug after the cyst content spillage when the rupture of the cyst or as a 
protoscolicide when PAIR is applied. 
Other drugs as nitazoxamide (at doses of 500mg/12h for 3-24 months) has been evaluated in 
the effectiveness in disseminated cystic echinococcosis (DCE) that failed to respond to 
surgical and antiparasitic therapy. Three patients improved: one with muscle involvement 
(clinico-radiological response), one with lung involvement (radiological response), and 
another with soft tissue and bony involvement (clinico-radiological response of soft tissue 
cysts) (Pérez-Molina et al., 2011).   
Benzimidazoles are contraindicated in pregnancy because they are teratogenic.  
Monitoring of the patients is needed and medical and laboratory examinations for adverse 
reactions are necessary initially every 2 weeks then monthly (WHO, 1996). Leukocyte counts 
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should be checked at 2-week intervals during the first 3 months because in rare instances 
severe and not always reversible leukopaenia has been observed in early phases of 
chemotherapy. Serum drug concentrations (ABZ-sulfoxide or MBZ parent compound) 
should be monitored after 2 and 4 weeks of chemotherapy, respectively, in order to identify 
levels too high (possibly toxic) or too low (ineffective). For MBZ, it has been recommended 
to determine serum or plasma levels 4 h after the morning dose. Oral drug doses can be 
adapted to individual patients in order to achieve adequate serum levels, but such attempts 
are not always effective. Unfortunately, only few laboratories have the capability to measure 
ABZ-sulfoxide or MBZ serum drug levels (see also section on AE). Follow-up examinations, 
including imaging if needed, should be carried out at intervals of about 3 to 6 months for 1 
to 3 years after termination of chemotherapy because of the relatively high rate of relapses.  
2.2.1.6.4 Vaccines  
A new vaccine against echinococcosis would be highly desirable in order to provide long-
term prevention of the disease and to complement control programs. Vaccines against ovine 
hydatidosis have demonstrated its efficacy when targeting the larval stage of the parasite 
(Lightowlers, 2001). However, if used in the field we would need to vaccinate all the animals 
in a herd to achieve good results and this would be very costly to control programs. 
Otherwise, a vaccine protecting dogs against the adult worm would have to be given to only 
a few animals to protect the environment, because dogs are less numerous than other 
animals in the herd. Also, domestic dogs are the key in the transmission to livestock and 
humans. Therefore, some authors have proposed a recombinant oral vaccine given to the 
small number of dogs keeping the herd would decrease the number of E. granulosus adult 
worms and, consequently, the number of infective eggs. This measure would help reduce 
the contamination risk factors for humans and livestock, would be cost-effective for the 
owners of the dogs, and could help increase the overall efficacy of control programs in 
endemic countries (Petavy, 2008).  
Some candidates have been used to induce immune response with vaccination. One of those 
is Eg-95 encoding gene that is expressed in the oncosphere, protoscoleces, and immature 
and mature adult worms of E. granulosus. EG95 vaccine antigen is a secreted 
glycosylphosphatydilinositol (GPI)-anchored protein containing a fibronectin type III 
domain, which is ubiquitous in modular proteins involved in cell adhesion. EG95 protein 
represents one of the targets of immunity induced by the vaccine because there is a high 
degree of sequence gene conservation between different isolates (Zhang, 2003). A mixture of 
different EG95 isoforms increases the ability of E. granulosus to invade different hosts and 
could possibly maximize vaccine efficacy (Haag, 2009). Other candidates for vaccine are the 
homologous sequences of two of the S3Pvac peptides, GK1 and KETc1, identified and 
further characterized in Taenia crassiceps WFU, Taenia solium, Taenia saginata, E. granulosus 
and E. multilocularis. Comparisons of the nucleotide and amino acid sequences coding for 
KETc1 and GK1 revealed significant homologies in these species and the results of a study 
indicate that GK1 and KETc1 may be considered candidates to be included in the 
formulation of a multivalent and multistage vaccine against these cestodiases because of 
their enhancing effects on other available vaccine candidates (Rassy, 2010).    
2.2.2 Alveolar echinococcosis (AE)  
Alveolar echinococcosis (AE) is an infection caused by the metacestode stage of E. 
multilocularis, which is characterised by a tumour-like, infiltrative and destructive growth 
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with the potential to induce serious disease with a high fatality rate.  Metacestodes develop 
primarily almost exclusively in the liver varying from small foci of a few millimetres in size 
to large areas of infiltration (15-20 cm.). From the liver, the metacestode tends to spread to 
both the adjacent and distant organs by infiltration or metastasis formation (Eckert, 1998). 
Cases of AE are characterized by an initial asymptomatic incubation period of 5-15 years 
duration and a subsequent chronic course. Fatality rate in untreated or inadequately treated 
persons is high.  
High burden of AE is known to be common in certain rural communities in China whilst it 
is generally rare and sporadic elsewhere. Recently, a study was carried out to estimate the 
global incidence of this disease by country (Torgerson, 2010). They undertook a detailed 
review of published literature and data from other sources suggesting that there are 
approximately 18,235 (CI 11,900–28,200) new cases of AE per annum globally with 16,629 
(91%) occurring in China and 1,606 outside China. Most of these cases are in regions where 
there is little treatment available and therefore will be fatal cases. They were able to calculate 
that AE results in a median of 666,434 DALYs per annum (CI 331,000-1.3 million). 
2.2.2.1 Clinical presentation of AE  
Age at the time of diagnosis of AE is significantly higher than for CE. The primary site of 
metacestode development is almost exclusively in the liver. The right lobe is predominantly 
infected, but the liver hilus together with one or two lobes may also be involved. Extra 
hepatic primarily locations are rare. During the infection, secondary echinococcosis may 
occur in variety of adjacent or distant organs. Symptoms of AE are primarily cholestatic 
jaundice (1/3 of cases) and/or epigastric pain (1/3 of the cases). In the remaining third of 
patients, AE is detected incidentally during medical examination for symptoms such as 
fatigue, weight loss, hepatomegaly, or abnormal routine laboratory findings.  
2.2.2.2 Classification and staging of AE 
PNM system for classification of human alveolar echinococcosis 
Classification of findings 
P: Hepatic localisation of the parasite 
PX: Primary lesion cannot be assessed 
P0: No detectable lesion in the liver 
P1: Peripheral lesions without proximal vascular and/or biliar involvement 
P2: Central lesions with proximal vascular and/or biliar involvement of one lobe (a) 
P3: Central lesions with hilar vascular and biliar involvement of both lobes and/or with 
involvement of two hepatic veins 
P4: Any liver lesion with extension along the vessels (b) and the biliary tree 
N: Extrahepatic involvement of neighbouring organs 
Diaphragm, lung, pleura, pericardium, heart, gastric and duodenal wall, adrenal glands, 
peritoneum, retroperitoneum, parietal wall (muscles, skin, bone), pancreas, regional lymph 
nodes, liver ligaments, kidney 
NX: Not evaluable 
N0: No regional involvement (see above) 
N1: Regional involvement of contiguous organs or tissues 
M: Absence or presence of distant metastases 
Lung, distant lymph nodes, spleen, CNS, orbital, bone, skin, muscle, distant peritoneum and 
retroperitoneum] 
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MX: Not completely evaluated 
M0: No metastasis(c) 
M1: Metastasis 
a. For classification, the plane projecting between the bed of the gallbladder and the 
inferior vena cava divides the liver in two lobes 
b. Vessels means inferior vena cava, portal vein and arteries 
c. Chest X-ray and cerebral CT negative 
Source: European Network for Concerted Surveillance of AE: PNM system for the 
classification of human cases of AE. 
 
 
Source: European Network for Concerted Surveillance of Alveolar Echinococcosis: PNM 
system for the classification of human cases of alveolar echinococcosis. 
2.2.2.3 Diagnosis of AE 
Diagnosis of AE is based on similar findings and criteria as in CE. 
Hepatic lesions are characterised in US and CT by heterogenous hypodense masses, often 
associated with necrotic cavities. The lesion contours are irregular and there is lack of a 
welldefined wall. Calcifications are often found and exhibit a typical pattern in regard to 
shape and distribution: clusters of microcalcifications or irregular plaque-like calcified foci 
are located in the central or peripheral parts of the lesions. Discrepancies between US and 
CT patterns can be found. Hyperechoic haemangioma-like nodules could represent early 
forms of AE lesions. Quite frequently an extension of the lesions beyond the liver is found 
toward diaphragm, lungs, pericardium, retroperitoneum, hepatoduodenal ligament and 
pancreas. 
Magnetic resonance imaging is used to observe compression or obstruction of inferior vena 
cava, the hepatic veins or the portal branches. Pathognomonic aspects are represented by 
multicystic honeycomb-like images. 
2.2.2.4 Laboratory findings of AE 
The routine laboratory tests do not yield specific findings. The blood sedimentation rate is 
elevated in most of the cases. The numbers of leucocytes and platelets may be depressed in 
patients with splenomegaly. Lymphopaenia is frequent in advanced cases, and eosinophilia 
is usually absent. Cholestasis with or without jaundice is observed in patients with 
intrahepatic bile duct compression or obstruction. Cholangitis and/or liver abscesses, which 
usually result from bile duct obstruction, are associated with typical alterations of the 
laboratory parameters. Hypergammaglobulinaemia is present in most of the patients and 
reflects the specific and polyclonal antibody response. In about one-half of the patients, the 
presence of specific anti-E. multilocularis – IgE can be demonstrated. 
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2.2.2.5 Immunodiagnosis of AE (table 3) 
 
Fisrt step: Primary antibody test 
Tests with high sensitivity and less specific value 
Subsequent steps 
Seronegative samples 
+ 
No suggestive images 
for AE 
Seronegative samples 
+ 
Suggestive images for 
AE 
Seropositive samples 
+ 
With or without suggestive 
images for AE 
No further serological 
follow-up. 
Persons with suspected 
infection risk may 
require repeated 
serological examinations 
after 3-6 months, and US 
imaging. 
Asymptomatic cases 
Extended and/or 
advanced imaging and 
repeated serological 
examinations. 
Fine needle biopsy for 
PCR or 
immunohistology may be 
considered in rare cases. 
If lesions are fully 
calcified, serological and 
imaging follow-up after 6 
months to confirm 
parasite abortion. 
Asymptomatic and 
symptomatic cases 
Secondary antibody test: 
Em2Plus-ELISA (Gottstein et al., 
1993) 
Em alkaline phosphatise- 
antigen-ELISA (Sarciron et al., 
1997) 
Immunoblot for specific bands or 
similar test 
Serological differential diagnosis 
for CE 
Symptomatic cases 
Consideration of surgical 
intervention 
and/or chemotherapy 
without further 
serological examinations 
Table 3. Approaches for immunodiagnosis of AE  
2.2.2.6 Pathological and histological examination of AE 
Metacestode of E. multilocularis typically exhibits an alveolar structure composed of 
numerous irregular cysts with diameters between less than 1 mm and 30 mm. when is 
examined in a macroscopic section of the liver. Due to necrosis of the lesion, cavities filled 
with liquid and necrotic material may be formed in the central parts of the parasite (Eckert, 
1998). Microscopically, the cysts consist of a relatively thin PAS-positive laminated layer and 
a delicate germinal layer often with only a few nuclei. Brood capsules and protoscoleces are 
rarely formed in the human host (Eckert, 1998). The cysts are surrounded by an inner zone 
of necrotic tissue and outer layers of histiocytes and lymphocytes. In later phases, tissue 
reactions of chronic inflammation, often with giant cell foreign body reaction, fibrous tissue 
and calcifications are seen around cysts.  
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2.2.2.7 Treatment of AE 
There are a variety of options to select the adequate treatment for each individual patient. 
Clinical experience is crucial for AE; therefore patients should be referred to a recognised 
national or regional reference centre. Early diagnosis of AE is of special importance for 
successful treatment because the lesion is acting as a malignant tumour. Screening 
programmes in Japan and Europe have shown that early diagnosis reduces mortality and 
morbidity due to AE. Some considerations for treatment of AE are generally accepted: the 
first choice treatment in all operable cases is radical surgical resection of the entire parasitic 
lesion from the liver and other affected organs, chemotherapy is indicated after radical 
surgery for a limited period of time, and long-term chemotherapy is mandatory after 
incomplete resection of the lesions, in inoperable patients and in AE patients after liver 
transplantation.  
Chemotherapy has several indications, as follows: 
 Applicable for limited period of time after radical surgery. Since residual parasite tissue 
may remain undetected at radical surgery, post-operative chemotherapy for at least 2 
years should be carried out and patients should be monitored for a minimum of 10 
years for possible recurrence 
 Long-term chemotherapy for several years is mandatory in inoperable AE patients, in 
cases following incomplete surgical resection of the parasite lesions and after liver 
transplantation 
 Pre-surgical chemotherapy is not indicated in cases of AE. However, in rare cases that 
surgery was contraindicated at the time of diagnosis of AE, surgery can be carried out 
after a prolonged course of chemotherapy. 
Benzimidazoles are preferentially used for AE: 
Mebendazole (MBZ) is given as 500-mg tablets in daily doses of 40-50 mg/kg bw in three 
divided doses postprandially. After an initial continuous treatment of 4 weeks, it is 
advisable to adjust the oral doses in order to obtain plasma drug levels of >250 nmol/l (= 74 
ng/ml). The duration of treatment is at least 2 years after radical surgery or continuously for 
many years in inoperable cases, as well as for patients who have undergone incomplete 
resection or liver transplantation. 
Albendazole (ABZ) is given as 400-mg tablet or as a 4% suspension at daily doses of 10 -15 
mg/kg bw (in two divided doses). In practice, a daily dose of 800 mg is given to adults, 
divided into two doses of 400 mg. Repeated cycles of 28 days treatment should be followed 
by a ‘wash out’ phase without chemotherapy of 14 days. However, data from the People’s 
Republic of China (Liu, 1997) and Italy indicate that a continuous ABZ treatment of AE is at 
least equally or more effective and well tolerated. The duration of necessary chemotherapy 
has not yet been determined but might well be life-long for most of the patients without 
complete resection of the AE lesions. 
Adverse effects of the chemotherapy with benzimidazoles are neutropaenia, alopecia and 
liver dysfunction. They are contraindicated in pregnancy due to its potential embryotoxicity 
and teratogenicity. Monitoring of the AE patients is similar to that in CE patients. A long-
term follow-up of more than 10 years is recommended.  
Interventional procedures are indicated for AE patients for whom surgery is 
contraindicated. Some of them are dilation and stent implantation in vessels or bile ducts, 
and endoscopic sclerosing of oesophageal varices.  
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Liver transplantation should only be considered in patients with very severe hilar extension, 
leading to uncontrolled biliary infections, symptomatic secondary biliary cirrhosis with 
ascites or severe variceal bleeding owing to portal hypertension (Bresson-Hadni, 1997). It 
requires long-term and continuous postoperative chemotherapy.  
2.2.3 Polycystic echinococcosis (PE) 
Forms of human polycystic echinococcosis (PE) are caused by E. vogeli and E. oligarthrus, 
which are confined in their distribution to Latin American countries. 
Metacestode of E. vogeli is characterized by its polycystic form filled with liquid with a 
tendency to form conglomerates with multiples small spaces inside. The most affected organ 
in the intermediate host is the liver. Metacestode of E. oligarthrus is similar to E. vogeli but 
the division in secondary spaces is less frequent and the laminar membrane is significantly 
thinner.  
Wild and domestic dogs as definitive hosts and paca (Cuniculus paca) as intermediate host 
participate in the life-cycle of E. vogeli. Polycystic echinococcosis due to E. vogeli has been 
communicated in the majority of the countries belonging to the neotropical region of 
America; including Panama, Colombia, Argentina, Ecuador, Brasil, Bolivia and 
Venezuela.  
E. oligarthrus is the unique Echinococcus specie that uses felids as definitive hosts. Infections 
naturally acquired have been demonstrated affecting pumas, jaguars, and other wild felids.  
2.2.3.1 Polycystic echinococcosis due to E. vogeli 
Clinical and radiological presentation is very similar to infection with multiple cysts of E. 
granulosus, and differential diagnosis depends on isolation of protoscoleces and 
morphological hook characteristics (D’Alessandro, 1997). Immunodiagnosis using a purified 
antigen of E. vogeli allowed discrimination between cases of PE and CE, but differentiation 
between PE and AE was not always possible (Gottstein, 1995). Albendazole with doses of 10 
mg/kg/day has been used for chemotherapy in six cases with success of treatment in four 
and improvement in two (D’Alessandro, 1997). 
2.2.3.2 Polycystic echinococcosis due to E. oligarthrus 
Only three human cases have been reported to date, two orbital in Venezuela and Surinam 
and one cardiac in Brazil with 2 cysts (1.5 cm diameter) (D’Alessandro, 1997). The diagnosis 
was based on morphology of protoscolex hooks.    
3. Conclusion 
Human echinococcosis is a zoonotic larval cestode disease usually caused by Echinococcus 
granulosus or E. multilocularis. Infection is chronic taking years for symptoms to develop. 
The medical impact of the late stages of human cystic or alveolar echinococcosis may be 
significant though morbidity and mortality are usually grossly under-reported in endemic 
areas. Because of diagnosis and treatment are difficult and reservoirs of infection are 
maintained in domestic livestock, dogs or wildlife, the disease is difficult to assess in 
terms of public health and requires long-term control interventions. Globally, 3.6 million 
disability-adjusted life-years (DALYs) could be lost due to echinoccocosis, and this 
disease is included in an important group of neglected non vector-borne zoonotic 
infections that are currently not sufficiently prioritised (WHO/DFID-AHP, 2006). 
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Echinococcosis is therefore a neglected disease which is under-reported and requires 
urgent attention in common with a number of other zoonoses in order to reduce 
morbidity and to help alleviate poverty in poor pastoral areas of the sub-tropics and 
temperate zones. It’s also difficult to formulate interventions and to apply cost-effective 
control programmes in this disease.  
Human behaviour is crucial in facilitating transmission of this infection between domestic 
animal hosts as a result of traditional pastoral and husbandry practices (Mcpherson, 2005; 
Craig, 2007). Dogs are also susceptible to infection with E. multilocularis and E. vogeli (whose 
intermediate hosts are principally rodents) and therefore dogs may constitute a greater 
zoonotic reservoir of infection compared to natural wild canid hosts. Peri-domestic 
transmission may occur and could for example sustain a level of transmission of E. 
multilocularis in highly endemic communities (Li, 2005), but is probably not responsible for 
long-term maintenance of these Echinococcus species adapted to small mammals. Therefore, 
echinococcosis is a disease where humans may acquire infection from wild or domestic 
animal hosts but the parasite cannot be directly transmitted between humans (Wolfe, 2007), 
and due to all of these concepts treatment of human echinococcosis cases will have no effect 
on pathogen transmission. We will need to apply interventions to reduce human exposure 
or break transmission cycles in order to control the disease. This places echinococcosis in a 
‘difficult-to-deal-with’ category; firstly, unlike the other neglected parasitic diseases humans 
can not act as a definitive host, and secondly, echinococcosis in livestock (or dogs) is not 
perceived as an animal health problem. 
Clinical symptoms and subsequent diagnosis occur in adults (20-60 years) but infections in 
children may also become symptomatic (Soriano Arandes et al., 2010), and imaging 
techniques are the basis for diagnosis preferably accompanied by a specific serological test 
(Craig et al., 2003). Surgical removal of cysts/cystic masses, cyst drainage or organ resection, 
are the main form of treatment, often supported by high dose albendazole cover; the latter 
also has a benefit in medically-only treated cases (WHO, 2001).  
The key factors of echinococcosis as a neglected disease are best described in a recent paper 
(Craig et al., 2007): 
 Human echinococcosis is a zoonosis, non vector-borne zoonosis, that is not transmitted 
between humans. Therefore, it’s a disease that is not amenable to vector-based control 
nor to direct human-treatment-approaches for case prevention.  
 Human CE and AE are chronic diseases with very long asymptomatic periods so that 
endemic communities and health authorities fail to properly recognise the negative 
health impacts. Prevalence values represent infection events some years previously. 
CE remains an important health problem in many regions of the world, both where 
no control measures have been implemented, and where control programs have been 
incompletely successful with ensuing re-emergence of the disease. In Spain, official 
data on CE show an increase in the proportion of intermediate hosts with CE during 
the last few years, and autochthonous pediatric patients have been reported, a sign of 
active local transmission of disease. However, several crucial aspects related to CE 
that would help better understand and control the disease have not been tackled 
appropriately, in particular the emergence of infection in specific geographical areas. 
The introduction of national registries for CE with online data entry, following the 
example set by the European Registry for Alveolar Echinococcosis, would help 
streamline data collection on CE by eliminating the need for evaluating and 
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integrating data from multiple regions, by avoiding duplication of data from patients 
who access several different health facilities over time, and by providing much 
needed clinical and epidemiological data that are currently accessible only to 
clinicians (Rojo-Vazquez et al., 2011). 
 Echinococcosis is difficult to detect or diagnose in humans without access to imaging 
tools (eg. ultrasound, CT scan), furthermore the basis for confirmatory laboratory 
diagnosis is usually expensive serological tests.  
 Treatment is very difficult and not always very effective, relying largely on costly major 
surgical or percutaneous hospital-based interventions to remove or sterilise cystic 
lesions. Furthermore, anthelmintic therapy is not ashighly effective as for other 
helminthic diseases (eg. gastro-intestinal helminthiases, schistosomiasis or 
onchocerciasis), and is based on long-term high dose albendazole usually re- quiring a 
minimum 6 months daily course, for which follow-up is very difficult especially in 
poor-resource areas. In this regard echinococcosis treatment more closely resembles 
tumour treatments or TB therapy, than that for a parasitic disease.  
 Medical records are usually not very explicit/specific, may involve complex follow-up 
notes, and may be dispersed across several specialities within/between 
hospitals/clinics and therefore data is not usually properly collated. 
 In under-developed regions, human echinococcosis generally occurs in poor, often 
remote marginalised pastoral societies that may be ethnically/socio-culturally isolated 
from the general population. Consequently they are not usually very well prioritised by 
the predominant agricultural-based community district health authorities, and so access 
to affordable health care is also poor and/or difficult. 
 The burden of echinococcosis disease is therefore difficult to quantify, and official 
hospital or district records often inaccurate, and in any case represent gross under- 
estimates of the real burden in an endemic area.  
 CE is a chronic, asymptomatic infection in domestic animals and is therefore also not 
recognised by livestock owners as an animal health or economic problem.  
 Dogs are the main carrier and spreader of the parasite, but are asymptomatic. In 
contrast to livestock numbers, official accurate estimates of dog population sizes 
(owned and stray) are almost never kept/known by municipal, veterinary or 
agricultural authorities. Canine echinococcosis is treatable with the anthelmintic 
praziquantel but requires frequent dosing. Unlike for rabies, there is currently no dog 
vaccine against canine echinococcosis.  
 Control of echinococcosis is difficult and exacerbated by the requirement of cooperation 
between agricultural/veterinary services and medical authorities.  
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